Autonomix Medical, Inc.

The Woodlands, Texas, United StatesFounded 20141–10 employeesautonomix.comLinkedIn

Autonomix Medical, Inc. is a medical device company developing precision nerve-targeted therapies for diseases of the peripheral nervous system. Its minimally invasive platform combines intravascular neural signal detection, targeted radio-frequency ablation, and real-time treatment verification, initially focusing on pain associated with pancreatic cancer while pursuing applications in hypertension, cardiology, pulmonology, and gastroenterology.

Visit autonomix.com ↗

Founded: 2014
Employees: 1–10

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Autonomix expanded both its scientific visibility and intellectual-property position during 2026. On Apr 29, 2026, the company announced acceptance of long-term pancreatic-cancer pain data at Digestive Disease Week, following selection of related work for the 2026 ASCO Gastrointestinal Cancers Symposium. On Jun 10, 2026, its nerve-sensing and transvascular denervation platform received a Top Cardiovascular Innovation Award at the Cardiovascular Research Technologies conference, and CEO Brad Hauser featured the platform in a new CEO Corner video. The company also reported a preclinical demonstration of renal-nerve sensing and neural-activity change on Jul 24, 2026. Patent activity accelerated: a U.S. patent covering feedback-guided precision neuromodulation was announced on Aug 4, 2026, a European patent on Sep 24, 2026, and Canadian catheter-technology coverage on Oct 5, 2026. Leadership and regulatory capabilities also broadened with Sandra Cohen Kalter joining the board on Sep 16, 2026 and Julie Manchester becoming Vice President of Regulatory Affairs and Quality in 2024. These milestones support a transition from platform development toward clinical validation and regulatory execution, while the technology remains investigational.

Market position

Autonomix operates at the intersection of interventional medical devices, neuromodulation, renal denervation, and pain management. Its differentiation is technological rather than scale-based: the company combines intravascular neural-signal detection, transvascular nerve mapping, radio-frequency ablation, and treatment verification in a single minimally invasive workflow. The platform is designed to help physicians sense, target, treat, and verify nerve activity, with embedded processing intended to preserve signal fidelity close to the point of detection. Initial applications include pancreatic-cancer pain, while the company is also pursuing hypertension, cardiology, pulmonology, and gastroenterology use cases. Compared with large device manufacturers, Autonomix is a small public company with approximately 1–10 employees and a narrower clinical footprint. Its potential advantage is the integration of sensing and therapy verification; its principal market constraints are clinical evidence requirements, FDA approval, commercialization resources, and competition from better-capitalized device platforms.

Growth & opportunities

Autonomix’s trajectory shows a progression from early private development to public-market financing and broader clinical and intellectual-property activity. The company was founded in 2014 and recorded early venture financing of $3.8 million in 2014, followed by $2.0 million in 2022, $675,000 in 2023, and $2.4 million in June 2023. It went public in January 2024 at a $5 share price, followed by a $10 million post-IPO equity round in November 2024. Additional post-IPO financing of $2.55 million in July 2025 and $5 million in November 2025 extended funding for development. Operationally, 2024 was an executive and regulatory inflection point: Brad Hauser became President and CEO in June, Jennifer Cook joined as Chief Business Officer in March, and Julie Manchester was appointed to lead regulatory affairs and quality in December. In 2026, conference acceptances, preclinical renal-nerve data, new patents, and the Precision-Guided Sense, Treat and Verify System indicate movement toward clinical and regulatory milestones.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Autonomix Medical, Inc. distinct

reccy insights

What makes Autonomix Medical, Inc. distinct

01Proprietary precision guidance technology enables physicians to sense, target, treat, and verify specific nerves through a minimally invasive procedure.
02The platform is designed to detect neural activity from within the body’s vasculature, positioning it as a potential GPS-like system for the nervous system.
03The custom sensing array achieves neural signal detection thresholds below 5 µV using prototype electrodes as small as 0.02 mm x 0.03 mm.
04Embedded processing at the point of detection is designed to minimize signal degradation and preserve high-fidelity neural data.
05The company is building an intellectual-property portfolio spanning 18 patent families and more than 120 issued or pending applications.

Technology & products2

Technology & products

Autonomix Precision-Guided Sense, Treat and Verify System
A catheter-based system designed to detect, target, ablate, and verify nerve activity with high sensitivity during a minimally invasive procedure.
CEO Corner segment on Autonomix platform technology
A video segment in which CEO Brad Hauser discusses scientific recognition of the company’s nerve-sensing platform and clinical plans.

Catheter-based microchip sensing array for neural signal detection
Custom sensing antennae array with detection thresholds below 5 µV
1 x 2 mm embedded microchip with localized signal processing
Transvascular nerve mapping and targeting technology
Proprietary radio-frequency ablation technology
Sense, treat, and verify platform for confirming ablation success

Recent updates8

Launches, partnerships and team changes from press coverage

Sep 16, 2026Team change
Autonomix appointed former Medtronic regulatory counsel Sandra Cohen Kalter to its Board of Directors, adding medical-device regulatory and transaction expertise.
biospace.com
Jun 10, 2026Product launch
Autonomix released a CEO Corner video segment featuring CEO Brad Hauser, highlighting scientific and clinical recognition of its nerve-sensing and transvascular denervation platform.
biospace.com
Jun 10, 2026Award
Top Cardiovascular Innovation Award
Apr 29, 2026Award
Abstract acceptance for presentation at Digestive Disease Week 2026
Jan 9, 2026Award
Abstract acceptance for poster presentation at 2026 ASCO Gastrointestinal Cancers Symposium
Dec 19, 2024Team change
Autonomix appointed Julie Manchester as Vice President, Regulatory Affairs and Quality to support clinical and regulatory initiatives for FDA approval.
tradingview.com
Jun 17, 2024Team change
Autonomix appointed Brad Hauser as President and Chief Executive Officer.
morningstar.com
Mar 19, 2024Team change
Autonomix appointed Jennifer Cook as Chief Business Officer.
globenewswire.com

Show all 8 updates

About Autonomix Medical, Inc.

Products: Autonomix Precision-Guided Sense, Treat and Verify System, CEO Corner segment on Autonomix platform technology
Leadership: Brad Hauser, President & Chief Executive OfficerJennifer Cook, Chief Business Officer
Focus areas: Medical devices, neurotechnology, nerve mapping, radio frequency ablation, diagnostics, therapeutics, interventional pain management, cardiology
Headquarters: The Woodlands, Texas, United States
Founded: 2014
Employees: 1–10
Patents granted: 74 (Crunchbase)
Trademarks: 3